Home » Newsletters » BioWorld Science

BioWorld Science

July 22, 1997

View Archived Issues

DepoTech issued U.S. patents covering DepoFoam technology

Company Profile: VidaMed

Immunex: Q2 1997 highlights

Pfizer: Q2 1997 highlights

Use of NK3 antagonists in various disorders claimed by SKB

Immunosuppressant peptides from Ajinomoto

Novel fibrinogen/integrin receptor antagonists described by Merck KGaA

Steroids from Jenapharm for contraception/HRT

Pylorid introduced in Argentina

Maternal infection associated with increased risk for cerebral palsy in term infants

Mitsubishi Chemical R&D status in Japan and overseas

Vyrex establishes proof of principle for CD-Tagging in human cells

Kyowa Hakko/Yoshitomi launch Imagenil in Japan

Prograf to be submitted in Japan for atopic dermatitis

Takeda's Atacand scheduled for European launch later this year

Toray/Daiichi codevelop analgesic

Mitsui Pharmaceuticals pipeline update

Genentech: Q2 1997 highlights

Bristol-Myers Squibb and GBF to discover lead anticancer compounds

Celltech: six-month highlights

U.S. patent allowance for Cypress Bioscience's IPM product

New biotechnology company focuses on RNA targets for infectious diseases

RPR seeks approval for Menorest in Japan

D1/D2 combination therapy results reported at the 16th IDF congress

Economics of diabetes discussed at IDF 97

Hyperglycemia increases the risk of cardiovascular disease: epidemiological evidence

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 16, 2026.
SERPINB1 as potential biomarker for spinocerebellar ataxia type 2
BioWorld Science
Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
JPM 2026: Year kicks off with biopharma Q4 revenue and guidance
BioWorld
It was a battle of the companies with drugs for transthyretin-mediated amyloidosis on the first day of the J.P. Morgan 2026 Healthcare Conference with Alnylam...